Source:http://linkedlifedata.com/resource/pubmed/id/20736079
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2011-4-18
|
| pubmed:abstractText |
Thirty-eight patients who met the diagnostic criteria for severe aplastic anemia underwent allogeneic hematopoietic stem cell transplantation (HSCT). The median patient age was 20 years (range, 14-36 years). Twenty-four patients were treatment-naïve, 11 had failed one or more previous courses of immunosuppressive therapy, and 3 had failed a previous HSCT. The conditioning regimen included fludarabine 30 mg/m(2)/day for 3 days (days -9, -8, and -7) and cyclophosphamide 50 mg/kg/day for 4 days (days -5, -4, -3, and -2). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and short-course methotrexate. All patients underwent transplantation with unmanipulated bone marrow as the stem cell source. The median total nucleated cell (TNC) dose was 2.43 × 10(8)/kg (range, 0.60-6.7 × 10(8)/ kg). The conditioning regimen was well tolerated, with minimal treatment-related mortality. Engraftment was observed in all patients after transplantation; the median time to engraftment of neutrophils and platelets was 18 and 23 days, respectively. Twenty-five of the 27 patients with available chimeric studies at day 180 maintained donor chimerism. Acute GVHD grade ?II was diagnosed in 4 patients (11%). Extensive chronic GVHD was observed in 8 patients (25%) who survived beyond day +100, at a median observation time of 43 months. Graft rejection with relapse of aplais was observed in one patient. The overall survival (OS) for the whole group was 79%. A trend toward improved OS was observed in the treatment-naïve patients (83% vs 71%), but this was statistically insignificant (P = .384). The fludarabine-based conditioning regimen used in this study with relatively young cohort of patients was well tolerated, with a low rate of rejection and treatment outcomes comparable to those seen in other, more intense and potentially more toxic conditioning regimens. Our results await validation in a larger study, optimally in a randomized controlled manner.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Vidarabine,
http://linkedlifedata.com/resource/pubmed/chemical/fludarabine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1523-6536
|
| pubmed:author |
pubmed-author:Al-AnaziKhalidK,
pubmed-author:Al-MoharebFahadF,
pubmed-author:Al-SharifFahadF,
pubmed-author:Al-ZahraniHazzaaH,
pubmed-author:AljurfMahmoudM,
pubmed-author:BakrMahmoudM,
pubmed-author:ChaudhriNaeemN,
pubmed-author:DOMESA LAL,
pubmed-author:ElhassanTusneemT,
pubmed-author:ElkumNaserN,
pubmed-author:HussainFazalF,
pubmed-author:IbrahimKhalidK,
pubmed-author:NassarAmrA,
pubmed-author:NurgatZubeirZ,
pubmed-author:PatelMoosaM,
pubmed-author:RasheedWalidW,
pubmed-author:SaidMohamedM,
pubmed-author:SalehAbu Jafar MohammedAJ
|
| pubmed:copyrightInfo |
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
717-22
|
| pubmed:meshHeading |
pubmed-meshheading:20736079-Adolescent,
pubmed-meshheading:20736079-Adult,
pubmed-meshheading:20736079-Anemia, Aplastic,
pubmed-meshheading:20736079-Antineoplastic Agents,
pubmed-meshheading:20736079-Blood Platelets,
pubmed-meshheading:20736079-Cyclophosphamide,
pubmed-meshheading:20736079-Cyclosporine,
pubmed-meshheading:20736079-Disease-Free Survival,
pubmed-meshheading:20736079-Female,
pubmed-meshheading:20736079-Graft Rejection,
pubmed-meshheading:20736079-Graft Survival,
pubmed-meshheading:20736079-Graft vs Host Disease,
pubmed-meshheading:20736079-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20736079-Humans,
pubmed-meshheading:20736079-Male,
pubmed-meshheading:20736079-Methotrexate,
pubmed-meshheading:20736079-Neutrophils,
pubmed-meshheading:20736079-Transplantation, Homologous,
pubmed-meshheading:20736079-Transplantation Chimera,
pubmed-meshheading:20736079-Transplantation Conditioning,
pubmed-meshheading:20736079-Treatment Outcome,
pubmed-meshheading:20736079-Vidarabine,
pubmed-meshheading:20736079-Young Adult
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
|
| pubmed:affiliation |
Adult HSCT Program, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
|
| pubmed:publicationType |
Journal Article
|